Optimization of Synthesis Parameters for Mesoporous Shell Formation on Magnetic Nanocores and Their Application as Nanocarriers for Docetaxel Cancer Drug

International Journal of Molecular Sciences

Ahmed Mohamed El-Toni²  Mohamed Abbas Ibrahim¹  Joselito Puzon Labis²  Aslam Khan² 

[1] Department of Pharmaceutics, Faculty of Pharmacy, King Saud University, Riyadh 11451, Saudi Arabia; E-Mail:;King Abdullah Institute for Nanotechnology, King Saud University, Riyadh 11451, Saudi Arabia; E-Mails:

关键词: mesoporous shell;    Fe₃O₄;    drug control release;    core-shell;    anionic surfactant;   

DOI  :  10.3390/ijms140611496

来源: mdpi

【 摘 要 】

In this work, Fe₃O₄@SiO₂ nanoparticles were coated with mesoporous silica shell by S⁻N⁺I⁻ pathway by using anionic surfactant (S⁻) and co-structure directing agent (N⁺). The role of co-structure directing agent (CSDA) is to assist the electrostatic interaction between negatively charged silica layers and the negatively charged surfactant molecules. Prior to the mesoporous shell formation step, magnetic cores were coated with a dense silica layer to prevent iron oxide cores from leaching into the mother system under any acidic circumstances. However, it was found that both dense and mesoporous coating parameters affect the textural properties of the produced mesoporous silica shell (i.e., surface area, pore volume and shell thickness). The synthesized Fe₃O₄@SiO₂@m-SiO₂ (MCMSS) nanoparticles have been characterized by low-angle X-ray diffraction, transmission electron microscopy (TEM), and N₂ adsorption-desorption analysis, and magnetic properties. The synthesized particles had dense and mesoporous silica shells of 8–37 nm and 26–50 nm, respectively. Furthermore, MCMSS possessed surface area of ca. 259–621 m²·g⁻¹, and pore volume of ca. 0.216–0.443 cc·g⁻¹. MCMSS showed docetaxcel cancer drug storage capacity of 25–33 w/w% and possessed control release from their mesochannels which suggest them as proper nanocarriers for docetaxcel molecules.

【 授权许可】

CC BY   
© 2013 by the authors; licensee MDPI, Basel, Switzerland